Marcos Rebollo-González

Mr. Marcos Rebollo-González


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2024 in British Journal of Dermatology
Verified
Journal Article
Closed access
LRLuis Requena
Luis Requena
MRMarta Rodríguez
Marta Rodríguez
RARuth Alonso-Alonso
Ruth Alonso-Alonso
MCMaría Dolores Mendoza Cembranos
María Dolores Mendoza Cembranos
JDJesús Frutos Díaz-Alejo
Jesús Frutos Díaz-Alejo
MPMiguel Ángel Piris
Miguel Ángel Piris
Background: Merkel cell carcinoma (MCC) is an aggressive malignant neuroendocrine tumour. There are two subsets of MCC, one related to Merkel cell polyomavirus (MCPyV) and the other to ultraviolet radiation (UVR). MCPyV-positive and MCPyV-negative MCCs have been considered to be different tumours, as the former harbour few DNA mutations and are not related to UVR, and the latter usually arise in sun-exposed areas and may be found in conjunction with other keratinocytic tumours, mostly squamous cell carcinomas. Two viral oncoproteins, large T antigen (LT; coded by MCPyV_gp3) and small T antigen (sT; coded by MCPyV_gp4), promote different carcinogenic pathways. Objectives: To determine which genes are differentially expressed in MCPyV-positive and MCPyV-negative MCC; to describe the mutational burden and the most frequently mutated genes in both MCC subtypes; and to identify the clinical and molecular factors that may be related to patient survival. Methods: Ninety-two patients with a diagnosis of MCC were identified from the medical databases of participating centres. To study gene expression, a customized panel of 172 genes was developed. Gene expression profiling was performed with nCounter technology. For mutational studies, a customized panel of 26 genes was designed. Somatic single nucleotide variants (SNVs) were identified following the GATK Best Practices workflow for somatic mutations. Results: The expression of LT enabled the series to be divided into two groups (LT positive, n = 55; LT negative, n = 37). Genes differentially expressed in LT-negative patients were related to epithelial differentiation, especially SOX9, or proliferation and the cell cycle (MYC, CDK6), among others. Congruently, LT displayed lower expression in SOX9-positive patients, and differentially expressed genes in SOX9-positive patients were related to epithelial/squamous differentiation. In LT-positive patients, the mean SNV frequency was 4.3; in LT-negative patients it was 10 (P = 0.03). On multivariate survival analysis, the expression of SNAI1 [hazard ratio (HR) 1.046, 95% confidence interval (CI) 1.007–1.086; P = 0.02] and CDK6 (HR 1.049, 95% CI 1.020–1.080; P = 0.001) were identified as risk factors. Conclusions: Tumours with weak LT expression tend to co-express genes related to squamous differentiation and the cell cycle, and to have a higher mutational burden. These findings are congruent with those of earlier studies.

13 May 2024 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
SRSocorro María Rodríguez-Pinilla
Socorro María Rodríguez-Pinilla
MRMarcos Rebollo-González
Marcos Rebollo-González
JDJesús Frutos Díaz-Alejo
Jesús Frutos Díaz-Alejo
RMRebeca Manso
Rebeca Manso
FPFrancisco Javier Díaz de la Pinta
Francisco Javier Díaz de la Pinta
Socorro María Rodríguez-PinillaSocorro María Rodríguez-Pinilla
Socorro María Rodríguez-Pinilla
We performed targeted next-generation sequencing of 62 genes, previously described as being mutated in T-cell lymphomas, in 15 formalin-fixed paraffin-embedded samples from patients with primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder.

Verified
Journal Article
Open access
PDF file
JDJesús Frutos Díaz-Alejo
Jesús Frutos Díaz-Alejo
IPIvan Prieto-Potin
Ivan Prieto-Potin
RMRebeca Manso
Rebeca Manso
SRSocorro María Rodríguez-Pinilla
Socorro María Rodríguez-Pinilla
MRMarcos Rebollo-González
Marcos Rebollo-González
Arantza OnaindiaArantza Onaindia
Arantza Onaindia
Anaplastic Large Cell Lymphoma (ALCL) represents a diverse group of mature T-Cell Lymphomas unified by strong CD30 expression but with different molecular and clinical subtypes. This review summarizes recent molecular advances in ALCL, highlighting key discoveries that have refined its classification, diagnosis, and therapeutic strategies. ALCL comprises four major entities: systemic ALK-positive ALCL, systemic ALK-negative ALCL, Breast Implant-Associated ALCL (BIA-ALCL), and primary cutaneous ALCL. Each subtype exhibits unique phenotypes, along with cytogenetic and molecular alterations that affect clinical outcomes. Nevertheless, different oncogenic mechanisms mediate STAT3 activation. In ALK-positive ALCL, ALK fusion proteins drive oncogenesis via constitutive activation of STAT3 and other signaling pathways. ALK-negative ALCL comprises heterogeneous genetic subtypes, in which JAK/STAT3 pathway alterations and novel gene fusions are gaining recognition as potential therapeutic targets. This review emphasizes the need for integrative molecular diagnostics to improve stratification of ALCL subtypes and targeted treatment approaches. Future research should focus on elucidating the biological mechanisms underlying these alterations and on translating molecular insights into clinical practice.

7 March 2023 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
RARuth Alonso-Alonso
Ruth Alonso-Alonso
SRSocorro María Rodríguez-Pinilla
Socorro María Rodríguez-Pinilla
NGNuria García-Díaz
Nuria García-Díaz
LTLaura Tomás-Roca
Laura Tomás-Roca
JBJennifer Borregón
Jennifer Borregón
Miguel PirisMiguel Piris
Miguel Piris
Gene profiling using a customized NanoString platform can be applied to routine mycosis fungoides (MF) samples, revealing their specific molecular features. This study shows that MF samples carry a signature derived from individual molecular features found in consecutive biopsies.

24 May 2026 in British Journal of Haematology
Verified
Journal Article
Closed access
JDJesús Frutos Díaz-Alejo
Jesús Frutos Díaz-Alejo
FPFrancisco Javier Díaz de la Pinta
Francisco Javier Díaz de la Pinta
LPLucía Pavía Pascual
Lucía Pavía Pascual
RMRebeca Manso
Rebeca Manso
DMDaniel Morillo
Daniel Morillo
Socorro María Rodríguez-PinillaSocorro María Rodríguez-Pinilla
Socorro María Rodríguez-Pinilla

19 September 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
RAR Alonso Alonso
R Alonso Alonso
JCJ Borregón Caselles
J Borregón Caselles
MRMarcos Rebollo-González
Marcos Rebollo-González
LMLm Gallego Manzano
Lm Gallego Manzano
JPJl Rodríguez Peralto
Jl Rodríguez Peralto
MPMa Piris Pinilla
Ma Piris Pinilla